Modality
Bispecific Ab
MOA
TYK2i
Target
GLP-1R
Pathway
Amyloid
PNHCLLMCL
Development Pipeline
Preclinical
~Jun 2014
→ ~Sep 2015
Phase 1
~Dec 2015
→ ~Mar 2017
Phase 2
Jun 2017
→ Apr 2029
Phase 2Current
NCT03995995
2,554 pts·MCL
2017-06→2029-04·Not yet recruiting
NCT05501301
304 pts·CLL
2025-12→2027-11·Terminated
2,858 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-11-141.6y awayPh2 Data· CLL
2029-04-083.0y awayPh2 Data· MCL
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
P2
Not yet…
P2
Termina…
Catalysts
Ph2 Data
2027-11-14 · 1.6y away
CLL
Ph2 Data
2029-04-08 · 3.0y away
MCL
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03995995 | Phase 2 | MCL | Not yet recr... | 2554 | CfB |
| NCT05501301 | Phase 2 | CLL | Terminated | 304 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| Tirzepatide | Eli Lilly | Approved | GLP-1R | |
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R |